Skip to content

Omnicell OMCL EV / EBITDA

EV / EBITDA at other companies

Baxter International logo
Baxter InternationalBAX
10.3×-1.6×
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
12.3×-6.5×
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
19×+3.3×
Guardian Pharmacy Services logo
Guardian Pharmacy ServicesGRDN
23.9×
Cardinal Health logo
Cardinal HealthCAH
16.9×+4.4×
Cencora logo
CencoraCOR
18.6×+2.4×

Other financials

Income statement

See full
Revenue$309.9M+14.9%
Gross profit$140.4M+26.5%
Operating income$16.9M+245%
Net income$11.4M+262%
EPS (diluted)$0.25+267%

Balance sheet

See full
Cash & equivalents$291.0M-29.8%
Total debt$34.3M-23.1%
Total equity$1.3B0.0%
Total assets$2.0B-6.8%

Cash flow

See full
Operating cash flow$54.5M+110%
CapEx$12.4M+11.3%
Free cash flow$42.1M+185%

Valuation

See full
Market cap$1.75B-7.2%
Enterprise value$1.49B-0.4%
P/E113.2×
P/S1.4×-0.2×

Profitability

See full
Gross margin43.5%+0.4pp
Operating margin2.7%+1.8pp
Net margin1.7%+1.1pp
FCF margin9.3%-1.7pp

Returns & leverage

See full
Return on equity1.6%+1.1pp
Debt / equity0.0×
Current ratio1.5×+0.1×

Where this comes from

Calculated from Omnicell’s reported figures.

Based on the most recent quarter.

The official record: Omnicell’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omnicell's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omnicell's EV / EBITDA?
Omnicell (OMCL) reported EV / EBITDA of 11.3× in Q1 2026.
How has Omnicell's EV / EBITDA changed year-over-year?
Omnicell's EV / EBITDA decreased by 17.9% year-over-year, from 13.8× to 11.3×.
What is the long-term trend for Omnicell's EV / EBITDA?
Over 5 years (2020 to 2025), Omnicell's EV / EBITDA has grown at a -15.5% compound annual growth rate (CAGR), from 50.2× to 21.7×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.